↓ Skip to main content

Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter Syndrome).

Overview of attention for article published in Orphanet Journal of Rare Diseases, March 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (77th percentile)
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

twitter
5 tweeters
facebook
1 Facebook page
googleplus
1 Google+ user

Citations

dimensions_citation
32 Dimensions

Readers on

mendeley
81 Mendeley
citeulike
2 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter Syndrome).
Published in
Orphanet Journal of Rare Diseases, March 2013
DOI 10.1186/1750-1172-8-42
Pubmed ID
Abstract

Mucopolysaccharidosis II (MPS II, Hunter syndrome) is a rare X-linked lysosomal storage disorder caused by the deficiency of iduronate-2-sulfatase (IDS). In affected patients, glycosaminoglycan (GAG) accumulates in the lysosomes of many organs and tissues contributing to the pathology associated with MPS II. The objective of this phase I/II clinical study was to evaluate the efficacy and safety of recombinant human iduronate-2-sulfatase (idursulfase beta, Hunterase®) in the treatment of MPS II.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 1%
Brazil 1 1%
Unknown 79 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 22 27%
Student > Bachelor 13 16%
Student > Master 9 11%
Student > Ph. D. Student 8 10%
Other 7 9%
Other 10 12%
Unknown 12 15%
Readers by discipline Count As %
Medicine and Dentistry 26 32%
Biochemistry, Genetics and Molecular Biology 13 16%
Agricultural and Biological Sciences 13 16%
Pharmacology, Toxicology and Pharmaceutical Science 3 4%
Computer Science 2 2%
Other 10 12%
Unknown 14 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 September 2013.
All research outputs
#1,046,283
of 5,037,615 outputs
Outputs from Orphanet Journal of Rare Diseases
#197
of 858 outputs
Outputs of similar age
#20,659
of 94,007 outputs
Outputs of similar age from Orphanet Journal of Rare Diseases
#13
of 52 outputs
Altmetric has tracked 5,037,615 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 858 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 94,007 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 52 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.